- The drug candidate, N17350, leverages the neutrophil elastase (ELANE) pathway, to achieve broad cancer-killing activity
- Onchilles is developing a pipeline of first-in-class biologic therapeutics based on novel innate immune biology to improve the treatment of all cancer types
SAN DIEGO, March 14, 2023 – Onchilles Pharma, a private biotech company developing new cancer therapeutics that leverage myeloid biology, announced today the presentation of preclinical data for N17350 at the American Association for Cancer Research (AACR) Annual Meeting 2023, to be held April 14 to 19 at the Orange County Convention Center in Orlando, Florida. Onchilles’ lead drug development candidate, N17350, is a first-in-class biologic therapeutic that is inspired by the immunobiology of neutrophils, a key part of the innate immune system, with the potential to be effective against a wide range of cancer types. The company is targeting to start first-in-human clinical trials in 2024.
- Poster Title: N17350 Selectively Kills Cancer Cells with Far Reaching Anti-Cancer Effects
- Date and Time: Wednesday, April 19, 9:00 AM to 12:30 PM ET
- Session Category: Immunology
- Session Title: Immune Mechanisms Mediated by Other Therapies
- Session Location: Section 24
- Poster Board Number: 3
- Abstract number: 6390
About N17350 and the ELANE Pathway
First described in research published in Cell from the lab of Onchilles’ Co-Founder Lev Becker, human neutrophils release catalytically active neutrophil elastase, called ELANE, to selectively kill many cancer cell types while sparing non-cancer cells. As part of innate immunity, neutrophils have broad efficacy and specificity to eliminate genetically diverse cellular threats. Research shows that ELANE initiates a complex killing mechanism that culminates in cancer cell apoptosis at the initial tumor site as well as increases adaptive immunity that attacks distant metastases. ELANE consistently activated this cancer-killing program in more than 45 different cancer cell lines but not in any non-cancer cells tested. To advance this research into a therapeutic, Onchilles generated N17350, a first-in-class biologic, to mobilize the ELANE-mediated cancer-killing pathway.
About Onchilles Pharma
Onchilles Pharma translates breakthrough research in novel innate immune biology into first-in-class therapeutics designed to selectively kill tumors and promote a systemic immune response. The company is developing a pipeline of first-in-class drug candidates based on novel druggable pathways that have the potential to be broadly effective against a wide range of cancers. Onchilles is headquartered at the Alexandria GradLabs in San Diego.
Company Contact: Peter Haberz, Ph.D., Vice President, Corporate Development, email@example.com